

PROVINCIAL FUNDING SUMMARY

Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory)

pERC Recommendation: Recommends

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: December 14, 2012

This information is current as of April 27, 2016. The use of this document is directed by [pCODR's Terms of Use](#).

Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Apr 1, 2016	In combination with rituximab for relapsed/refractory patients with indolent NHL or mantle cell lymphoma. As single agent bendamustine for the treatment of relapsed or refractory indolent NHL or mantle cell lymphoma in patients who are refractory or intolerant to rituximab. Jun 1, 2013 Funded for First-line: Patients with previously untreated indolent non-Hodgkin lymphoma (follicular, marginal zone, lymphoplasmacytic) and mantle cell lymphoma. NOTE: A BCCA "Compassionate Access Program" request with appropriate clinical information for each patient must be approved prior to treatment
		Nov 1, 2012	Relapsed or refractory indolent non-Hodgkin lymphoma (follicular, marginal zone, lymphoplasmacytic) and mantle cell lymphoma: advanced stage symptomatic disease requiring therapy; relapsed or refractory disease no longer controlled by BCCA standard treatment including, involved field radiation (for disease symptomatic at only one site amenable to radiation), alkylating agents such as cyclophosphamide and chlorambucil, fludarabine, 90Y-ibritumomab tiuxetan or 131I-tositumomab, gemcitabine and cisplatin (for mantle cell lymphoma only). NOTE: A BCCA "Compassionate Access Program" request with appropriate clinical information for each patient must be approved prior to treatment.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
AB	Funded	Mar 25, 2013	<p>In combination with rituximab as first-line therapy in patients with indolent CD20 positive NHL or mantle cell lymphoma with an ECOG performance status of equal or less than 2;</p> <p>OR</p> <p>In combination with rituximab for relapsed/refractory patients with indolent NHL or mantle cell lymphoma.</p> <p>Updated March 5, 2014 to allow single agent bendamustine for the treatment of relapsed or refractory indolent NHL in patients who are refractory or intolerant to rituximab.</p>
SK	Funded	Apr 3, 2013	<p>Treatment of patients with indolent non-Hodgkin’s lymphoma (NHL) including follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma and non-transplant eligible patients with mantle cell lymphoma, in combination with Rituximab (B-R) for a maximum of 6 cycles as a first line option;</p> <p>OR</p> <p>As one line of therapy in the relapsed setting in patients eligible for Rituximab re-treatment (e.g., in patients with progressive disease or relapse >1 year after last Rituximab dose).</p>

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
MB	Funded	Mar 19, 2013	<p>Indolent Non-Hodgkin's Lymphoma, Untreated Inclusion Criteria: In combination with Rituximab, for the first line treatment of patients with</p> <ul style="list-style-type: none"> • Stage III or IV indolent non-Hodgkin's Lymphoma (e.g. Marginal Zone Lymphoma, Follicular Lymphoma, Waldenström Macroglobulinemia, Lymphoplasmocytic Lymphoma) AND • Symptomatic disease, or other accepted indications for treatment, AND • Confirmed CD 20 antigen positive disease, AND • An Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, AND • Adequate bone marrow, hepatic, and renal function. <p>Indolent Non-Hodgkin's Lymphoma, Relapsed Inclusion criteria: In combination with Rituximab, for the treatment of patients with</p> <ul style="list-style-type: none"> • Stage III or IV indolent non-Hodgkin's Lymphoma (e.g. Marginal Zone Lymphoma, Follicular Lymphoma, Waldenström Macroglobulinemia, Lymphoplasmocytic Lymphoma) AND • Symptomatic disease, or other accepted indications for treatment, AND • Refractory or relapsed disease after prior chemotherapy AND • Confirmed CD 20 antigen positive disease, AND • An Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less AND • Adequate bone marrow, hepatic, and renal function. <p>Mantle Cell Lymphoma, Untreated Inclusion criteria: In combination with Rituximab, for the first line treatment of patients with</p> <ul style="list-style-type: none"> • Stage III or IV Mantle Cell Lymphoma, AND • Aged > 65 years old, or are ineligible for aggressive therapy, AND • symptomatic disease, or other accepted indications for treatment, AND • confirmed CD 20 antigen positive disease, AND • an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, AND • adequate bone marrow, hepatic, and renal function. <p>Mantle Cell Lymphoma, Relapsed Inclusion criteria: In combination with Rituximab, for the treatment of patients, aged > 65 years old, or are ineligible for aggressive therapy, with</p> <ul style="list-style-type: none"> • Stage III or IV Mantle Cell Lymphoma, AND • symptomatic disease, or other accepted indications for treatment, AND • refractory or relapsed disease after prior chemotherapy AND • confirmed CD 20 antigen positive disease, AND • Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less AND • adequate bone marrow, hepatic, and renal function.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
ON	Funded	May 21, 2013	<p>For the First Line Treatment of Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma where the patient meets all of the following criteria:</p> <ul style="list-style-type: none"> - Bendamustine is used in combination with rituximab in the first line setting in patients with indolent CD20 positive non-Hodgkin's lymphoma or mantle cell lymphoma; and - The patient has an ECOG performance status of less than or equal to 2. <p>Dosing: Bendamustine 90mg/m² on Days 1 and 2 of a 28-day cycle to a maximum of 6 cycles (combination therapy)</p> <p>Notes: a) Bendamustine is not funded if used as a single agent b) Patients who receive first line rituximab bendamustine would be eligible for rituximab maintenance provided that the maintenance rituximab funding criteria are met.</p> <p>For the Relapsed/Refractory Treatment of Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma where the patient meets all of the following criteria:</p> <ul style="list-style-type: none"> - Bendamustine is used in the relapsed/refractory setting in patients with indolent CD20 positive non-Hodgkin's lymphoma or mantle cell lymphoma when used in combination with rituximab, where the combination of fludarabine-rituximab could previously have been a therapeutic option. <p>Dosing: Bendamustine 90mg/m² on Days 1 and 2 of a 28-day cycle to a maximum of 6 cycles (combination therapy)</p> <p>Notes: a) Bendamustine is not funded if used as a single agent b) A patient whose disease has relapsed from rituximab is eligible for rituximab funding provided that the funding criteria for rituximab retreatment are met (e.g., the patient has sustained a response and has remained treatment free for at least one year's duration following the last dose of rituximab received).</p>
NS	Funded	July 10, 2013	<p>Initial Therapy - in combination with rituximab as a first-line option.</p> <p>Relapsed/Refractory Therapy - in combination with rituximab in the relapsed/refractory setting in bendamustine-naïve patients who previously received rituximab-based therapy, achieved a response of at least one year's duration since the last rituximab administration and chooses a bendamustine combination as a therapeutic option.</p> <p>Retreatment - in combination with rituximab as a retreatment option in patients who previously received rituximab-bendamustine-based therapy and achieved a response of at least one year's duration since the last rituximab administration and/or two years from the last bendamustine dose.</p>

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
NB	Funded	Feb 1, 2014	<p>1. For first-line therapy for patients diagnosed with Indolent CD20 Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma and an ECOG performance status of less than or equal to 2, when used in combination with rituximab.</p> <p>2. In combination with rituximab for relapsed/refractory therapy for bendamustine-naïve patients with Indolent CD20 Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma who previously received rituximab-based therapy, sustained a response and had remained treatment free for at least one year's duration following the last dose of rituximab.</p>
NL	Funded	Jan 1, 2013	<p>For first line indolent β-cell non-Hodgkin's (iNHL) lymphoma and Mantle Cell Lymphoma (MCL);</p> <p>For relapsed indolent β-cell non-Hodgkin's (iNHL) lymphoma and Mantle Cell Lymphoma who did not respond or who had progressed during or shortly following treatment with a rituximab regimen</p>
PEI	Funded	Apr 8, 2014	<p>For use in the relapsed/refractory setting in patients with indolent Non-Hodgkin Lymphoma (iNHL) and Mantle Cell Lymphoma (MCL) when used in combination with rituximab, where the combination of fludarabine-rituximab could previously have been a therapeutic option.</p>